Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia
Schneider-Helmert D
European Neurology (1987) · n=14
Across 14 middle-aged chronic insomniacs given DSIP for seven consecutive nights under double-blind placebo control, night-sleep efficiency rose to control-population values and the effect persisted through the first placebo washout night — the cleanest single-investigator EEG-monitored evidence for DSIP in disturbed human sleep.
This 1987 European Neurology paper by Dietrich Schneider-Helmert — the European clinician most closely associated with DSIP's clinical-trial era — is the most rigorous single demonstration that the peptide produces sleep-architecture effects in chronic insomnia under placebo-controlled conditions. The investigator enrolled 14 middle-aged adults with severe chronic psychophysiological insomnia and treated them under a double-blind placebo-controlled design with intravenous DSIP for seven consecutive nights, with polysomnograms recorded on the placebo-baseline night, the first DSIP night, the seventh DSIP night, and a first-post-treatment placebo washout night. Both immediate (first-dose) and cumulative (seven-night) effects on sleep efficiency and architecture were observed, with sleep-efficiency values rising to the range of age-matched normal sleepers. The most notable finding was that the improvement persisted through the first post-treatment placebo night — suggesting a delayed-onset or carryover pharmacological effect rather than a same-night sedative action. Daytime alertness and cognitive-performance assessments also improved during the treatment period. The paper is the companion to Schneider-Helmert's 1986 European Neurology study in middle-aged and elderly insomniacs (Schneider-Helmert 1986) and together they constitute the strongest single-investigator clinical evidence base for DSIP in human sleep disturbance.
This is a 14-patient trial — small even by 1980s sleep-medicine standards, and the effect sizes reported on individual sleep-architecture variables have correspondingly wide confidence intervals. The single-investigator design means the findings have not been independently replicated at equivalent rigour outside the Schneider-Helmert programme. The "carryover into placebo washout" finding is mechanistically interesting but would today be analysed under more demanding statistical-conventions; readers should not over-read the persistence claim. The IV administration route used in the trial does not map to modern compounded-pharmacy subcutaneous DSIP protocols — pharmacokinetics, bioavailability, and effective peripheral concentrations are different. The molecular target through which DSIP produces sleep effects has never been identified in the four decades since the peptide was sequenced (Schoenenberger 1978), which means even strong clinical findings sit on an incompletely characterised mechanism. The DSIP literature peaked in clinical-trial activity in the late 1980s and tapered through the 1990s and 2000s without producing a regulatory-grade development programme; readers should weight that history when extrapolating from this paper to current sleep-medicine practice.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.